

## CYP3A5 Variant Allele Frequencies in Dutch Caucasians

RON H.N. VAN SCHAİK,<sup>1\*</sup> ILSE P. VAN DER HEIDEN,<sup>1</sup> JOHN N. VAN DEN ANKER,<sup>2,3,4</sup> and JAN LINDEMANS<sup>1</sup>

**Background:** Enzymes of the cytochrome P450 3A (CYP3A) family are responsible for the metabolism of >50% of currently prescribed drugs. CYP3A5 is expressed in a limited number of individuals. The absence of CYP3A5 expression in ~70% of Caucasians was recently correlated to a genetic polymorphism (CYP3A5\*3). Because CYP3A5 may represent up to 50% of total CYP3A protein in individuals polymorphically expressing CYP3A5, it may have a major role in variation of CYP3A-mediated drug metabolism. Using sequencing, have been identified (Hustert et al. *Pharmacogenetics* 2001;11:773–9; Kuehl et al. *Nat Genet* 2001;27:383–91) variant alleles \*2 through \*7 for CYP3A5. Detection of CYP3A5 variant alleles, and knowledge about their allelic frequency in specific ethnic groups, is important to establish the clinical relevance of screening for these polymorphisms to optimize pharmacotherapy.

**Methods:** In a group of 500 healthy Dutch Caucasian blood donors, we determined the allelic frequency of the CYP3A5\*2, \*3, \*4, \*5, \*6, and \*7 alleles by use of newly developed PCR-restriction fragment length polymorphism assays.

**Results:** The frequency of the defective CYP3A5\*3 allele in the Dutch Caucasian population was 91%, followed by the CYP3A5\*2 (1%) and CYP3A5\*6 (0.1%) alleles. The CYP3A5\*4, \*5, and \*7 alleles were not detected.

**Conclusions:** On the basis of its allelic frequency, screening for the CYP3A5\*3 allele in the Caucasian population is extremely relevant. In addition, screening for the CYP3A5\*2 allele may be taken into consideration in individuals heterozygous for the CYP3A5\*3 allele.

The CYP3A5\*4, \*5, \*6, and \*7 alleles have low allelic frequencies that do not support initial screening.

© 2002 American Association for Clinical Chemistry

The CYP3A isoenzymes constitute the largest portion of cytochrome P450 protein in the liver and small intestine (1–3). The four members of this subfamily, CYP3A4, CYP3A5, CYP3A7, and CYP3A43 (4, 5), are located adjacent to each other on chromosome 7q21 and are responsible for the metabolism of 50–60% of all currently prescribed drugs. In addition, two pseudogenes, CYP3AP1 and CYP3AP2, have been identified (6). To date, CYP3A4 has been regarded as the most important enzyme of this subfamily because it forms the bulk of CYP3A protein and mRNA in the liver in most individuals (1–3). Its catalytic activity may show up to 90-fold variation (7). CYP3A7 is expressed mainly during fetal life where it accounts for ~50% of the total CYP protein (8). After birth, expression is usually silenced. For the recently described CYP3A43, no protein expression data are currently available (9). CYP3A5 protein was previously detected in the livers of some, but not all, adult Caucasian individuals (8, 10–14). The basis for this variation in expression was not known.

In a recent study, Kuehl et al. (15) demonstrated that only people with at least one CYP3A5\*1 allele actually expressed CYP3A5 protein. Using DNA sequencing, they identified the CYP3A5\*3 and \*6 alleles. The single-nucleotide polymorphisms in these alleles produced alternative splicing and protein truncation and thus absence of CYP3A5 activity. In another study, the livers of 10% of Caucasian individuals expressed CYP3A5 to a high extent (high expressers), whereas the remaining individuals showed on average nine times less activity (low expressers) (7). The major determinant for this variation in expression was a single-nucleotide polymorphism at position 6986, which in the *g.6986G* allele (CYP3A5\*3) led to alternative splicing of CYP3A5 transcripts and absence of CYP3A5 protein; the *g.6986A* allele (CYP3A5\*1) correlated with high expression (7, 15). Because CYP3A5 may represent up to 50% of the total hepatic CYP3A content in

Departments of <sup>1</sup>Clinical Chemistry and <sup>2</sup>Pediatrics, Sophia Children's Hospital, Erasmus MC, 3000 CA Rotterdam, The Netherlands.

<sup>3</sup>Division of Pediatric Clinical Pharmacology, Children's National Medical Center, Washington, DC 20010.

<sup>4</sup>Departments of Pediatrics and Pharmacology, George Washington University Medical Center, Washington, DC 20037.

\*Address correspondence to this author at: Department of Clinical Chemistry, Erasmus MC, PO Box 2040, 3000 CA Rotterdam, The Netherlands. Fax 31-10-436-7894; e-mail vanschaik@ckcl.azr.nl.

Received May 31, 2002; accepted June 26, 2002.

people expressing *CYP3A5*, this gene may be the most important genetic contributor to interindividual and interracial differences in *CYP3A*-dependent drug clearance. Detection of *CYP3A5* variant alleles, and knowledge about the allelic frequencies in the population, will be extremely useful in establishing the clinical relevance of *CYP3A5* genotyping to optimize pharmacotherapy. To date, several variant alleles have been identified (*CYP3A5*\*2 through \*7) by sequencing (7, 10, 15, 16). For screening purposes, we developed PCR-restriction fragment length polymorphism (PCR-RFLP) assays for the detection of *CYP3A5* variant alleles. We report here the allelic frequencies of *CYP3A5* variant alleles in a group of 500 healthy Dutch Caucasian volunteers.

### Materials and Methods

#### SAMPLES AND DNA ISOLATION

After receiving informed consent, we obtained EDTA-whole blood from 500 healthy Dutch Caucasian volunteers. We isolated genomic DNA from 300  $\mu$ L of blood with the GenomicPrep Blood DNA Isolation Kit (Amersham Pharmacia Biotech) and estimated DNA yields by measuring the absorbance at 260 nm ( $A_{260}$ ). The Medical Ethical Committee of the University Hospital Rotterdam approved the study.

#### PCR-RFLP FOR *CYP3A5* VARIANT ALLELES

For a 50- $\mu$ L PCR, we used  $\sim$ 50 ng of genomic DNA. The PCR mixture contained 1 $\times$  buffer [10 mM Tris-HCl, pH 8.3, 1.5 mM MgCl<sub>2</sub>, 50 mM KCl, and 10 mg/L gelatin (Perkin-Elmer)], 0.2 mM each of the deoxynucleotide triphosphates (Roche), 1.25 U of AmpliTaq Gold (Perkin-Elmer), and 40 pmol each of the forward and reverse primers (Table 1). The underlined nucleotides are mismatches with the *CYP3A5* sequence, creating restriction sites in the PCR product. PCR conditions were as follows: 7 min at 94  $^{\circ}$ C; 35 cycles of 1 min at 94  $^{\circ}$ C, 1 min at 55  $^{\circ}$ C, and 1 min at 72  $^{\circ}$ C; and finally 7 min at 72  $^{\circ}$ C. The PCR

product was sequenced, confirming that indeed only the *CYP3A5* gene was amplified. The PCR product (10  $\mu$ L) was then digested with the appropriate restriction enzyme (Roche; Table 1) in a total volume of 15  $\mu$ L for 2 h at 37  $^{\circ}$ C and subsequently analyzed on a 4% agarose/Tris-borate-EDTA gel with ethidium bromide staining. The fragments obtained for wild-type and variant alleles are indicated in Table 1. We confirmed the presence of variant alleles of *CYP3A5* by direct sequencing of the PCR product on an automated ABI 310 capillary sequencer (Perkin-Elmer), using the Big Dye Terminator Cycle Sequencing Kit (Perkin-Elmer).

### Results

On the basis of the published *CYP3A5* variant alleles, we developed specific PCR-RFLP tests for *CYP3A5*\*2 through \*7 and applied those in a large-scale genotyping study on samples obtained from 500 healthy Caucasian volunteers (Fig. 1). The frequency of individuals that were wild type, heterozygous, or homozygous for the variant alleles is depicted in Table 2. The *CYP3A5*\*3 allele was abundantly present in our population, with an allelic frequency of 91.7%. Only one individual was homozygous wild type for *CYP3A5*\*3. The *CYP3A5*\*2 allele was found in 10 individuals, all heterozygotes, giving an allelic frequency of 1%. One individual was heterozygous for the *CYP3A5*\*6 allele. The *CYP3A5*\*4, \*5, and \*7 alleles were not detected in our study population. Among the 84 persons who were heterozygous or wild type for the *CYP3A5*\*3 allele, only one was also heterozygous for another variant allele (*CYP3A5*\*2). Because heterozygotes and wild types for *CYP3A5*\*3 may have *CYP3A5* activity, we estimate that 83% of Dutch Caucasians do not have *CYP3A5* enzymatic activity.

### Discussion

*CYP3A* enzymes are the predominant cytochrome P450 proteins in the human liver and play an important role in

**Table 1. PCR-RFLP primers, size of PCR product, restriction enzymes used, and sizes of fragments obtained with wild-type and variant alleles for *CYP3A5*.**

<i>CYP3A5</i> allele	Primers <sup>a</sup>	PCR product size, bp	Enzyme	Fragment sizes, bp	
				Wild-type allele	Variant allele
*2	5'-CTGTTTCTTTCCTCCAGGC-3' 5'-CTCCATTCCCTGGAGACTTG-3'	269	<i>TasI</i>	269	182, 87
*3	5'-CATCAGTTAGTAGACAGATGA-3' 5'-GGTCCAAACAGGGAAGAAATA-3'	293	<i>SspI</i>	148, 125, 20	168, 125
*4	5'-TCGACTCTCTCAACAATCC <u>TC</u> -3' 5'-AAAGTGTGTGAGGGCTCTCGA-3'	281	<i>TaqI</i>	261, 20	241, 20
*5	5'-CCATGAAGATCACCACAAC-3' 5'-CCTGTCCCGAGATTCAT <u>GC</u> -3'	240	<i>NlaIII</i>	226, 14	189, 37, 14
*6	5'-GTGGGGTGTGACAGCTAAAG-3' 5'-TGGAAGATGATTCAGCAGATAGT-3'	495	<i>DdeI</i>	230, 137, 103, 25	230, 137, 128
*7	5'-CTTCAATAGTACTGCATGGAC-3' 5'-CTGTACCACGGCATCATAG <u>CT</u> -3'	108	<i>DdeI</i>	61, 24, 22	41, 24, 22, 20

<sup>a</sup> Mismatches with the *CYP3A5* sequence are underlined.




Fig. 1. PCR-RFLP analyses for *CYP3A5* variant alleles.

(A), *CYP3A5*\*2; (B), *CYP3A5*\*3; (C), *CYP3A5*\*6. M, 50-bp DNA ladder; wt, wild type; het, heterozygote; N, negative control (water); P, undigested PCR product; hom, homozygous variant.

the metabolism of numerous exogenous and endogenous substrates. *CYP3A5* is polymorphically expressed and may account for up to 50% of CYP3A content (15). Recently, six variant alleles were described (7, 15). Homozygosity for the allele *g.6986G* was strongly correlated with decreased *CYP3A5* activity [factor of 2–3 (15)], whereas the wild-type *CYP3A5*\*1 allele (*g.6986A*), present in either homozygous or heterozygous form, correlated with high *CYP3A5* activity. In addition, individuals with a *CYP3A5*\*1 allele had threefold higher total CYP3A protein when compared with individuals homozygous for *CYP3A5*\*3 (15). Thus, *CYP3A5* expression may be the most important factor determining the total CYP3A content of the human liver.

In a large-scale screening for *CYP3A5* variant alleles among 500 healthy individuals, we conclude that the *CYP3A5*\*3 allele is abundantly present in the Dutch Caucasian population, displaying an allelic frequency of 91%. This finding is in agreement with the reported frequency of 95% found in 183 samples from Caucasian patients from Germany and Switzerland (7). For comparison, the *CYP3A5*\*3 allele was detected in 73% of Chinese, 71% of Japanese, 70% of Korean, and 27% of African-American individuals (7). The *CYP3A5*\*2 allele, encoding a *g.27289C*→*A* allele in exon 11, was found in 2% of the individuals (allelic frequency, 1%) and may thus be regarded as a genetic polymorphism in this population (17).

A previous study involving 19 Caucasian individuals reported an allelic frequency of 5% ( $n = 19$ ) (10). This allele was not found when 45 African-American genomic DNA samples were investigated, suggesting that in this ethnic group the allelic frequency is <1% (7). Heterozygosity for the *CYP3A5*\*2 allele, however, may potentially affect *CYP3A5* expression in individuals who are already heterozygous for *CYP3A5*\*3. We found only one individual heterozygous for both the *CYP3A5*\*2 and \*3 alleles, and this individual may thus lack *CYP3A5* activity despite being heterozygous for the *CYP3A5*\*3 allele. The allelic frequencies of the *CYP3A5*\*4, \*5, \*6, and \*7 alleles were  $\leq 0.1\%$ , and these variant alleles are therefore regarded as less relevant for screening purposes in the Caucasian population. In African Americans, the *CYP3A5*\*6 allele (a *g.14690G*→*A* variant in exon 2, leading to the skipping of exon 7) has an allelic frequency of 13% ( $n = 45$ ) (7), suggesting a significant difference in the distribution of this allele between African Americans and Caucasians. This also holds for the *CYP3A5*\*7 allele, which encodes a single nucleotide (T) insertion at *g.27131* that leads to termination of the open reading frame; this allele was found in 9 of 45 African Americans, giving an allelic frequency of 10% (7). Apparently, the *CYP3A5*\*6 and/or the *CYP3A5*\*7 alleles do not cosegregate with the *CYP3A5*\*3 allele in Caucasians, as was suggested for African Americans (7). On the basis of the *CYP3A5* variant alleles detected in our group of 500 Dutch Caucasians, we deduce that 83% may have low expression of *CYP3A5*. This is in agreement with the finding that 10% of Caucasians were high expressers of *CYP3A5* (7).

**Table 2. Allelic frequencies of *CYP3A5* variant alleles in the Dutch Caucasian population ( $n = 500$ ).**

<i>CYP3A5</i> allele	AA <sup>a</sup> change	Wild type	Heterozygotes	Homozygotes	Allelic frequency
*2	T398N	0.980	0.020	0.000	0.010
*3	Splicing Defect	0.002	0.167	0.831	0.917
*4	Q200R	1.000	0.000	0.000	0.000
*5	Splicing Defect	1.000	0.000	0.000	0.000
*6	Splicing Defect	0.998	0.002	0.000	0.001
*7	Frameshift	1.000	0.000	0.000	0.000

<sup>a</sup> AA, amino acid.

In conclusion, we showed that screening for the *CYP3A5*\*3 allele is relevant in the Caucasian population. Genotyping for the *CYP3A5*\*2 allele in *CYP3A5*\*3 heterozygotes may subsequently be performed. In addition, we presented simple DNA-based tests that can be used to investigate interindividual differences in *CYP3A5* expression. This will greatly facilitate studies on the relevance of pharmacogenetics for *CYP3A* genes with respect to disease risk and to the pharmacokinetics and pharmacodynamics of many drugs.

### References

1. Cholerton S, Daly AK, Idle JR. The role of individual human cytochromes P450 in drug metabolism and clinical response. *Trends Pharmacol Sci* 1992;13:434–9.
2. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. *J Pharmacol Exp Ther* 1994;270:414–23.
3. Thummel KE, Wilkinson GR. In vitro and in vivo drug interactions involving human CYP3A. *Annu Rev Pharmacol Toxicol* 1998;38:389–430.
4. Hashimoto H, Toide K, Kitamura R, Fujita M, Tagawa S, Itoh S, et al. Gene structure of CYP3A4, an adult-specific form of cytochrome P450 in human livers, and its transcriptional control. *Eur J Biochem* 1993;218:585–95.
5. Gellner K, Eiselt R, Hustert E, Arnold H, Koch I, Haberl M, et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. *Pharmacogenetics* 2001;11:111–21.
6. Finta C, Zaphiropoulos PG. The human cytochrome P450 3A locus: gene evolution by capture of downstream exons. *Gene* 2000;260:13–23.
7. Hustert E, Haberl M, Burk O, Wolbold R, He YQ, Klein K, et al. The genetic determinants of the CYP3A5 polymorphism. *Pharmacogenetics* 2001;11:773–9.
8. Wrighton SA, Ring BJ, Watkins PB, VandenBranden M. Identification of a polymorphically expressed member of the human cytochrome P-450III family. *Mol Pharmacol* 1989;36:97–105.
9. Domanski TL, Finta C, Halpert JR, Zaphiropoulos PG. cDNA cloning and initial characterization of CYP3A43, a novel human cytochrome P450. *Mol Pharmacol* 2001;59:386–92.
10. Jounaidi Y, Hyraillies V, Gervot L, Maurel P. Detection of CYP3A5 allelic variant: a candidate for the polymorphic expression of the protein? *Biochem Biophys Res Commun* 1996;221:466–70.
11. Schuetz JD, Molowa DT, Guzelian PS. Characterization of a cDNA encoding a new member of the glucocorticoid-responsive cytochromes P450 in human liver. *Arch Biochem Biophys* 1989;274:355–65.
12. Wrighton SA, VandenBranden M. Isolation and characterization of human fetal liver cytochrome P450HLP2: a third member of the P450III gene family. *Arch Biochem Biophys* 1989;268:144–51.
13. Paine MF, Khalighi M, Fisher JM, Shen DD, Kunze KL, Marsh CL, et al. Characterization of interintestinal and intrainestinal variations in human CYP3A-dependent metabolism. *J Pharmacol Exp Ther* 1997;283:1552–62.
14. Aoyama T, Yamano S, Waxman DJ, Lapenson DP, Meyer UA, Fischer V, et al. Cytochrome P-450 hPCN3, a novel cytochrome P-450 IIIA gene product that is differentially expressed in adult human liver: cDNA and deduced amino acid sequence and distinct specificities of cDNA-expressed hPCN1 and hPCN3 for the metabolism of steroid hormones and cyclosporine. *J Biol Chem* 1989;264:10388–95.
15. Kuehl P, Zhang J, Lin Y, Lamba J, Assem M, Schuetz J, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. *Nat Genet* 2001;27:383–91.
16. Chou FC, Tzeng SJ, Huang JD. Genetic polymorphism of cytochrome P450 3A5 in Chinese. *Drug Metab Dispos* 2001;29:1205–9.
17. Meyer UA. Genotype or phenotype: the definition of a pharmacogenetic polymorphism. *Pharmacogenetics* 1991;1:66–7.